Last update: Feb. 20, 2021
Poorly safe. Evaluate carefully.
Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives).
Read the Comment.
Butalbital is a barbiturate with general properties similar to those of amobarbital. It is a sedative-hypnotic drug.
It is used to treat pain in combination preparations with paracetamol or caffeine.
Disused medicine due to risk of overdose and abuse (Suddock 2020).
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight, low protein binding and very long half-life) makes transfer to milk possible in amounts that could be significant.
A 7-day-old newborn, whose mother was taking a butalbital compound (50 mg) -paracetamol-caffeine four times a day, developed sedation, lethargy, hypotonia, insufficient nutrition, and vomiting. The infant had urine butalbital levels (Vohra 2019).
Safer known alternatives are preferable, especially during the neonatal period and in cases of prematurity (Burch 2020 y 2019, Worthington 2013).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM